Dr. Kirchhoff has broad interests in tropical medicine and diseases prevalent in developing countries. His primary focus is on Chagas disease, a major cause of morbidity and death in Latin America, and its protozoan etiologic agent, Trypanosoma cruzi . His current work is directed toward the development of serodiagnostic assays for T. cruzi infection based on chimeric recombinant proteins and radiolabeled parasite lysates.  This work is largely carried out through Goldfinch Diagnostics Inc., a start-up company founded by Dr. Kirchhoff that is an affiliate of the Technology Innovation Center on the Oakdale Campus.

Honors, Awards, and Organizations

• Diplomate, American Board of Internal Medicine
• Syntex Scholars Award
• Established Investigator, American Heart Association
• Member, American Society of Tropical Medicine and Hygiene
• Member, American Association of Blood Banks
• Scholar Award, National Blood Foundation
• Tibbetts Award, NIH Small Business Innovation Research Program

Recent Publications

1. Kirchhoff LV, Paredes P, Lomeli-Guerrero A, Paredes-Espinoza M, Ron-Guerrero C, Delgado-Mejia M, Munoz‑Pena JG. Transfusion-associated Chagas' disease (American trypanosomiasis) in Mexico: Implications for transfusion medicine in the United States. Transfusion 2006;46:298‑304
2. Duprey ZH, Steurer FJ, Rooney JA, Kirchhoff LV, Jackson JE, Rowton ED, et al. Canine visceral leishmaniasis, United States and Canada, 2000–2003. Emerg Infect Dis 2006;12:440‑446.
3. Chang C‑D, Cheng KY, Jiang LX, Salbilla VA, Haller AS, Yem AW, Bryant JD, Kirchhoff LV, Leiby DA, Schochetman G, Shah DO.  Evaluation of a prototype Trypanosoma cruzi antibody assay using recombinant antigens on a fully automated chemiluminescence analyzer. Transfusion 2006;46:1737-1744.

Medical School:
Yale University

Graduate School:
Epidemiology, Yale University

Residency:
University of Michigan

Fellowship:
University of Virginia
Laboratories of Clinical Investigation and Parasitic Diseases, NIH